These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 6799391)

  • 21. Limited junctional diversity in kappa light chains. Junctional sequences from CD43+B220+ early B cell progenitors resemble those from peripheral B cells.
    Victor KD; Vu K; Feeney AJ
    J Immunol; 1994 Apr; 152(7):3467-75. PubMed ID: 7511648
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Large cytoplasmic inclusion body kappa-chain has unusual intrachain disulfide bonding.
    Jäck HM; Sloan B; Grisham G; Reason D; Wabl M
    J Immunol; 1993 Jun; 150(11):4928-33. PubMed ID: 8388424
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Production of anti-tumor human monoclonal antibodies using different approaches.
    Liu H; Xu ZL; Wang Y; Yang L; Feng O; Li Y; Wang YM; Zhang GG
    Hum Antibodies Hybridomas; 1993 Jan; 4(1):2-8. PubMed ID: 8381684
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Myeloma with multiple rearranged immunoglobulin kappa genes: only one kappa gene codes for kappa chains.
    Storb U; Arp B; Wilson R
    Nucleic Acids Res; 1980 Oct; 8(20):4681-7. PubMed ID: 6255428
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High-avidity human IgG kappa monoclonal antibodies from a novel strain of minilocus transgenic mice.
    Fishwild DM; O'Donnell SL; Bengoechea T; Hudson DV; Harding F; Bernhard SL; Jones D; Kay RM; Higgins KM; Schramm SR; Lonberg N
    Nat Biotechnol; 1996 Jul; 14(7):845-51. PubMed ID: 9631008
    [TBL] [Abstract][Full Text] [Related]  

  • 26. IgM expressed by leukemic CD5(+) B cells binds mouse immunoglobulin light chain.
    Weston KM; Tangye SG; Dunn RD; Smith A; Morris MB; Raison RL
    J Mol Recognit; 2001; 14(4):245-53. PubMed ID: 11500971
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preferential species-restricted heavy/light chain pairing in rat/mouse quadromas. Implications for a single-step purification of bispecific antibodies.
    Lindhofer H; Mocikat R; Steipe B; Thierfelder S
    J Immunol; 1995 Jul; 155(1):219-25. PubMed ID: 7602098
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Restriction in the repertoire of the immunoglobulin light chain subgroup in pathological cold agglutinins with anti-Pr specificity.
    Leo A; Kreft H; Hack H; Kempf T; Roelcke D
    Vox Sang; 2004 Feb; 86(2):141-7. PubMed ID: 15023185
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Somatic cell hybridization between bovine leukemia virus-infected lymphocytes and murine plasma cell tumors: cell fusion studies with bovine cells.
    Davidson I; Katzav S; Ungar-Waron H; Eshhar Z; Haimovich J; Trainin Z
    Mol Immunol; 1982 Jul; 19(7):893-9. PubMed ID: 6289087
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Kinetics of amino acid transport by human-mouse myeloma hybrids--difference between human immunoglobulin producers and nonproducers.
    Cieplinski W; Tomicic T; Schwink A; Hajjar J
    Cancer Biochem Biophys; 1985 Feb; 7(4):309-16. PubMed ID: 3978588
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pituitary adenylate cyclase-activating polypeptide is a potent inhibitor of the growth of light chain-secreting human multiple myeloma cells.
    Li M; Cortez S; Nakamachi T; Batuman V; Arimura A
    Cancer Res; 2006 Sep; 66(17):8796-803. PubMed ID: 16951196
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Selective assembly of laminin variants by human carcinoma cells.
    Wewer UM; Wayner EA; Hoffstrom BG; Lan F; Meyer-Nielsen B; Engvall E; Albrechtsen R
    Lab Invest; 1994 Nov; 71(5):719-30. PubMed ID: 7967523
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Light chain contribution to specificity in anti-DNA antibodies.
    Ibrahim SM; Weigert M; Basu C; Erikson J; Radic MZ
    J Immunol; 1995 Sep; 155(6):3223-33. PubMed ID: 7673735
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antigen-specific human antibodies from mice comprising four distinct genetic modifications.
    Lonberg N; Taylor LD; Harding FA; Trounstine M; Higgins KM; Schramm SR; Kuo CC; Mashayekh R; Wymore K; McCabe JG
    Nature; 1994 Apr; 368(6474):856-9. PubMed ID: 8159246
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A simple and rapid protocol for the sequence determination of functional kappa light chain cDNAs from aberrant-chain-positive murine hybridomas.
    Yuan X; Gubbins MJ; Berry JD
    J Immunol Methods; 2004 Nov; 294(1-2):199-207. PubMed ID: 15604028
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The WI-L2-729-HF2 human hybridoma system. Stable hybrids at high frequency.
    Heitzmann JG; Cohn M
    Mol Biol Med; 1983 Sep; 1(2):235-43. PubMed ID: 6334216
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A human myeloma cell line suitable for the generation of human monoclonal antibodies.
    Karpas A; Dremucheva A; Czepulkowski BH
    Proc Natl Acad Sci U S A; 2001 Feb; 98(4):1799-804. PubMed ID: 11172031
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chimeric murine-human antibodies directed against folate binding receptor are efficient mediators of ovarian carcinoma cell killing.
    Coney LR; Mezzanzanica D; Sanborn D; Casalini P; Colnaghi MI; Zurawski VR
    Cancer Res; 1994 May; 54(9):2448-55. PubMed ID: 7512887
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Establishment and characterization of two human myeloma cell lines secreting kappa light chains.
    Eton O; Scheinberg DA; Houghton AN
    Leukemia; 1989 Oct; 3(10):729-35. PubMed ID: 2506399
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Purification of monoclonal antibodies with light-chain heterogeneity produced by mouse hybridomas raised with NS-1 myelomas: application of hydrophobic interaction high-performance liquid chromatography.
    Abe N; Inouye K
    J Biochem Biophys Methods; 1993 Oct; 27(3):215-27. PubMed ID: 7505010
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.